Sign In
6 Nov 2013 07:00
BLOCK LISTING APPLICATION TO AIM
VERNALIS PLC (the "Company")
6 November 2013
Vernalis plc (LSE: VER) announces that an application has been made to the London Stock Exchange for the admission to trading on AIM of a block listing of securities in respect of 350,000 Ordinary Shares of 1 pence each ("Shares") in the Company. The Shares will be issued from time to time pursuant to the exercise of options under the Vernalis plc 2007 Long Term Incentive Plan.
The Shares will be issued credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares of the Company. It is expected that admission will become effective on 11 November 2013.
Enquiries:
Vernalis Contacts: | +44 (0) 118 938 0015 |
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
| |
Oriel Securities Limited: | +44 (0) 20 7710 7600 |
Jonathan Senior Giles Balleny
| |
Brunswick Group: | +44 (0) 20 7404 5959 |
Jon Coles
|
Notes to Editors
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris Pharma.
For further information about Vernalis, please visit www.vernalis.com
Follow the stocks
